Latest Regulatory News

James Hardie Industries plc reported a slight dip in FY25 sales and profits but met guidance, while announcing a transformative acquisition of The AZEK Company Inc to accelerate growth and synergies.

James Hardie has released its financial results for the fourth quarter and full year ended March 31, 2025, accompanied by a suite of detailed reports filed with both the ASX and SEC.

Janus Electric Holdings Limited will have its trading suspension lifted and resume quotation on the ASX from 21 May 2025 after meeting key listing requirements.

Macarthur Minerals has secured $250,000 through unsecured convertible notes to bolster its working capital and support ongoing operations amid challenging market conditions.

Yowie Group Ltd has firmly rejected the validity of director removal and nomination notices purportedly from Keybridge Capital, while confirming its status as Keybridge’s largest creditor with over $6.6 million owed. The company also detailed a recent share placement amid ongoing regulatory scrutiny.

The ASX has formally queried Bougainville Copper Limited following an unexpected surge in its share price and trading volume, seeking clarity on any undisclosed information that might explain the market activity.

Kingston Resources has agreed to sell its Misima Gold-Silver Project for $95 million, bolstering its balance sheet to accelerate growth at the Mineral Hill gold-copper operation. The transaction positions Kingston to expand production and exploration in the southern Cobar Basin.

Sunstone Metals Ltd has had its trading suspension lifted following a Federal Court decision and the release of a cleansing prospectus, signaling a fresh chapter for the mining company on the ASX.

Zoono Group has inked a five-year exclusive contract with Sharpak and OSY to apply its antimicrobial technology on UK soft fruit packaging, aiming to reduce food waste and boost shelf-life.

Clarity Pharmaceuticals has initiated its second registrational Phase III AMPLIFY trial for the Cu-SAR-bisPSMA PET imaging agent targeting biochemical recurrence of prostate cancer. The multi-centre study aims to generate critical data supporting FDA approval and could redefine prostate cancer diagnostics.

Atomo Diagnostics has released a Target Market Determination for a new capital raising involving options and shares, including a $1 million Share Purchase Plan and placement offer. The move targets eligible Australian shareholders and aims to bolster the company’s financial position amid a speculative investment environment.

Atomo Diagnostics Limited has announced a capital raising initiative comprising a Share Purchase Plan (SPP) and a Placement, aiming to raise up to $1 million through the SPP and additional funds via a Placement, subject to shareholder approval at a June 23 meeting.